Cite
APA Citation
Jenkins, K., Johnson, P., Zhang, M., Guzman, W., Eskiocak, U., McLaughlin, M., O'Toole, C., Pederzoli-Ribeil, M., Park, M., Williams, J., Karow, M., O'Neil, J., Clackson, T., & O'Hagan, R. (n.d.). 587 Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models. Journal for immunotherapy of cancer, 8, A351. http://access.bl.uk/ark:/81055/vdc_100144731425.0x000006